levels in malnourished children were reported without any comments about the presence of associated neurological signs. 6, 7 In protein-energy malnutrition (PEM), the authors correlated the presence of neurological signs akin to vitamin E deficiency with low serum ␣-tocopherol levels suggesting a possible causal association. 8 Down regulation of ␣-tocopherol transfer protein gene expression, analogous to protein deficiency in rats, is an interesting postulate besides poor intake, impaired absorption and possible pancreatic and biliary insufficiency. 9 In developing countries, the impact of the observed vitamin E deficiency in PEM and the potential reversal, stabilization or prevention of neurological symptoms with vitamin E therapy may be of consequence. 4, 10, 11 The treatment schedule varies with underlying etiology, severity and cause of vitamin E malabsorption. 4 In PEM besides calories, vitamins, minerals and trace elements are administered but there is no reported study on vitamin E administration. The documentation of vitamin E deficiency in PEM subjects and the detection of neurological deficits among PEM children with vitamin E deficiency was the rationale to administer vitamin E in PEM for possible therapeutic benefit. 8 
Patients and Methods

Study design
A prospective therapeutic intervention trial with oral aqueous ␣-tocopherol was carried out in moderate PEM subjects. Neurological signs, ␣-tocopherol levels, total lipid levels, and electrophysiological parameters were studied before and after vitamin E supplementation. Patients served as their own controls and a control group was also incorporated in the study.
Patient population
Children attending the pediatric outpatient department and rural health centres of the All India Institute of Medical Sciences, New Delhi, India were screened. A total of 120 children of either sex between the ages of 3 and 8 years with moderate PEM were enrolled. Moderate PEM was identified on the basis of weight-for-age criteria using the norms of the Indian Academy of Pediatrics (weight between 50 and 70 per cent of the reference values). 12 Twenty children with acute severe intercurrent illnesses, neurological illnesses, neurodevelopmental and mental retardation were excluded. The remaining 100 children comprised the study population. Fifty normal (weight ≥80 per cent of reference) age-matched subjects with similar exclusion criteria were studied in the same manner for neurological signs and vitamin E levels and acted as reference subjects. They were recruited from the immunization clinics at both centres.
Treatment controls
Controls included 22 moderate PEM subjects, every fourth patient with low serum ␣-tocopherol levels, and eight PEM subjects with normal serum ␣-tocopherol levels (details below).
Clinical data
Clinical history, examination and anthropometric data were recorded on a predesigned proforma. Detailed neurological examination on all subjects and controls was conducted by two clinicians independently, and only those positive findings for which there was interobserver agreement were recorded as positive. The clinicians were 'blinded' as to the treatment and control groups. Features suggestive of malnutrition and associated vitamin deficiencies were recorded.
Laboratory investigations
Serum ␣-tocopherol was measured by the modified spectrophotometric technique of Hashim and Schuttinger. 13 Total lipid levels, total cholesterol, high density lipoproteins (HDL), low density lipoproteins (LDL), and triglycerides were measured using standard kits. The serum ␣-tocopherol: total lipids ratio was calculated; a ratio <0.6 is reported to provide a better approximation of vitamin E status. 14 Creatine phosphokinase (CPK) levels were also measured using standard kits.
Electroneurophysiological data included visual evoked responses, brainstem auditory evoked potentials and somatosensory evoked potentials which were studied before and after therapeutic intervention in 10 subjects and 15 normal children.
Therapeutic intervention
Informed consent was taken from all patients. Out of 100 PEM subjects, four were excluded owing to unwillingness to participate, non-compliance or follow-up drop out. Eight subjects with normal tocopherol levels (>0.35 mg/dl) were put in the control group. Out of the 88 PEM subjects with low tocopherol levels (<0.35 mg/dl) every fourth child (n = 22) was put in the control group and the remaining 66 in the treatment group. The treatment group received aqueous ␣-tocopherol acetate in a dose of 100 mg/kg/day; the control group received no medication.
The water soluble liquid preparation was given for a period of 6 weeks as a single dose with breakfast, as recommended in the literature for attaining optimal effects. 1 The patients in both groups were advised to continue with the same diet pattern. Only intercurrent illnesses, if any, were treated. No other supplements were given for the period of study. Patients were recalled every 2 weeks to ensure compliance by checking the medication left in the bottle provided.
Patient follow-up
After 6 weeks of therapy, the patients were re-evaluated. A detailed neurological examination was repeated and ␣-tocopherol levels, lipid profile, creatine phosphokinase, and electroneurophysiological studies were re-evaluated at the end of the therapy.
Statistical analysis Statistical analysis was done using the test of proportions and the McNemar test.
Results
Clinical data
Birthweight, gestational age, and perinatal characteristics of the PEM group and normal children were similar; 10 per cent of the PEM subjects had perinatal illnesses compared to 4 per cent of the normal children (p > 0.5).
Presenting symptoms that brought the PEM group to the hospital included upper respiratory infections (72 per cent), diarrhea (22 per cent), malabsorption (2 per cent), skin rash (13 per cent), and urinary complaints (7 per cent). Examination revealed muscle wasting (80 per cent), anemia (64 per cent), clinical vitamin A deficiency (11 per cent), hair and skin changes (9 per cent), pedal edema (6 per cent), stomatitis and cheilosis (8 per cent), rickets (2 per cent), and multiple vitamin deficiencies including vitamins B, A and D (6 per cent).
Neurological examination
Absent tandem walking, diminished vibration sense, diminished joint/position sense, dysdiadokinesia, ataxia and hyporeflexia were statistically significant in the PEM group compared to 50 normal children (p < 0.001) ( Table 1) . Finger agnosia, impaired left-right discrimination and synkinetic movements were significant in the PEM group (p < 0.01). The abnormal neurological signs were similar among different ages within the PEM group.
Vitamin E status
The mean serum ␣-tocopherol level in the PEM group was 0.26 ± 0.11 mg/dl, compared to 0.41 ± 0.09 mg/dl in normal children (reported norms ranged from 0.35 to 0.5 mg/dl). 5, 14 We applied the lowest accepted norm to identify vitamin E deficiency. Ninety-two per cent of PEM children had serum ␣-tocopherol levels <0.35 mg/dl, while only 12 per cent age-matched normal children had low levels (p < 0.01). The ␣-tocopherol levels did not vary with the age of the subjects within the PEM group. The ␣-tocopherol:total lipid ratio in the PEM group was 0.47 ± 0.14 compared to 0.72 ± 0.12 for age-matched normal children (p < 0.01). The ratio was <0.6 in 92 per cent of PEM and in 18 per cent of normal children. There was good concordance between the low serum ␣-tocopherol and tocopherol:total lipid ratio. These data indicate the presence of significant ␣-tocopherol deficiency in the PEM children.
Electroneurophysiological studies
Brainstem auditory evoked potentials, visual evoked responses, and somatosensory evoked potentials in 10 PEM children before and after therapy and in 15 normal children revealed that electroneurophysiological data was comparable to normative data in tocopherol deficient PEM and normal subjects. 8 Vitamin E supplementation Therapeutic compliance was ensured, and the subjects tolerated the therapy well. No significant side-effects, gastrointestinal upsets or diarrhea, were observed.
Post-treatment Evaluation
Neurological examination
The PEM subjects (n = 96) included 30 controls, comprising eight with normal serum ␣-tocopherol levels and 22 with low levels, and 66 from the treatment group. The neurological signs of the eight subjects in the control group who had normal tocopherol levels were comparable to those with low tocopherol levels. The neurological signs among the controls and the treatment group of PEM subjects were similar before vitamin E supplementation ( Table 2 ). After 6 weeks of treatment, the McNemar test on neurological signs of both groups before and after treatment (Table 3) , revealed a statistically significant improvement in vitamin E-treated PEM subjects with regard to vibration, joint position sense, dysdiadokinesia, ataxia, tandem walking, and hyporeflexia (p < 0.001). Other neurological signs, including intention tremors, two-point discrimination, synkinetic movements, finger agnosia, and left-right discrimination, did not show any statistically significant change. On the other hand, the control group exhibited no significant change in the neurological signs on re-evaluation.
Vitamin E status
Serum ␣-tocopherol and total lipids were estimated in the patients after 6 weeks of therapy. The serum ␣-tocopherol levels before and after therapy in both the groups (Table 4) revealed that controls continue to have low serum tocopherol levels (mean first level: 0.34 ± 0.15 mg/dl; second level >6 weeks later: 0.32 ± 0.14 mg/dl), while 56/66 (84.8 per cent) PEM patients had normal tocopherol levels after vitamin E therapy (mean pretreatment: 0.27 ± 0.06 mg/dl; post-treatment: 0.42 ± 0.09 mg/dl). The statistical test of proportion applied to the controls and the post-treatment group was highly significant (p < 0.001). Similarly, vitamin E:lipid ratio normalized in 57/66 (86.3 per cent) PEM subjects after vitamin E supplementation; there was no change in the control group (Table 5 ). The statistical test of proportion was again highly significant (p < 0.001).
Lipid profile
Total cholesterol, HDL, LDL, and triglyceride levels were evaluated in 10 PEM patients before and after therapy ( Table 6 ). The mean total cholesterol, LDL, triglycerides, and total lipids increased after therapy with vitamin E but the increase was not statistically significant (p > 0.05). 
Creatine phosphokinase
The CPK levels reduced from a mean of 471 IU/l before therapy to 198 IU/l after therapy (Table 6 ). This was statistically significant (p < 0.01).
Electroneurophysiological data
Brainstem auditory-evoked potentials, visualevoked responses and somatosensory-evoked potentials in 10 PEM subjects before and after therapy with vitamin E (Table 7) , revealed no statistically significant difference after treatment.
Discussion Vitamin E is nature's most effective lipid soluble, chain breaking antioxidant, protecting cell membranes from peroxidative damage. 3 It is also involved in controlling brain prostaglandin and leukotriene synthesis and also in regulating nucleic acid synthesis and gene expression. 15, 16 The beneficial role of vitamin E was first reported in 1928, when paralysis was observed in suckling offspring of vitamin E-deficient mother rats. 17 The neuropathological lesions associated with vitamin E deficiency include axonal degeneration in the posterior columns and a selective loss of large calibre myelinated sensory axons in the spinal cord and peripheral nerves. 18 The primary manifestations of prolonged vitamin E deficiency include spinocerebellar ataxia, skeletal myopathy, and retinopathy. Other symptoms include diminished proprioception and vibration sensation, ophthalmoplegia, ptosis, proximal weakness, dysarthria, visual field loss, scoliosis, and pes cavus. Not all patients reveal the entire spectrum of clinical findings. 4, 19 More rapid and severe neurological dysfunction results in the immature system of young animals and human infants compared to adults. 20 Previous studies have shown low vitamin E levels in PEM subjects but no correlation is reported with neurological abnormalities except impaired motor and sensory nerve conductions. 6, 21 A recent experimental study in rats observed the downregulation of ␣-tocopherol transfer protein gene expression which helps in maintaining ␣-tocopherol concentrations in protein deprivation. 9 The authors reported significant posterior column deficits, cerebellar deficits and problems with fine motor co-ordination in the PEM children. The presence of neurological signs correlated with vitamin E deficiency. 8 Studies indicate potential reversibility and preventability of the neurological symptoms with appropriate and timely treatment. reversal or prevention of clinical neurological abnormalities has been shown when vitamin E deficiency was corrected before the age of 3 years, whereas only partial improvement in neurological function was achieved when therapy was initiated after the age of 5 years. 11 Treatment schedules are not standardized and need to be tailored according to underlying etiology, severity, and cause of vitamin E deficiency. Doses have varied from 10 IU to 200 IU/kg/day and normalization may take about 3 weeks. 4 A linear relationship has been found between the tocopherol content of tissues and the logarithm of dose administered when vitamin E is fed to experimental animals and humans. The duration of vitamin E supplementation influences the tissue concentration of vitamin E. 22 A recent study revealed a non-linear rise of plasma ␣-tocopherol concentrations because the newly absorbed vitamin E partly replaces the ␣-tocopherol in circulating lipoproteins. 5 Vitamin E should be given as a single morning dose with breakfast, concurrent with the time of maximal bile flow. 4 In this study, the PEM subjects were given a single dose of vitamin E with breakfast with no other supplements. No significant adverse effects have been reported with oral vitamin E supplementation except in infants where E-ferol syndrome, necrotizing enterocolitis and sepsis were reported. 23, 24 In this study all subjects tolerated vitamin E without significant side-effects.
The convincing evidence favoring the neurological benefit of vitamin E in man is the demonstration of reversal and prevention of the associated neurological symptoms after vitamin E administration. 2, 10, 20 Four large studies, in which 39 children were treated showed that 1-4 years of vitamin E repletion prevented neurological abnormalities in 29 per cent of the patients, stabilized 28 per cent and improved 46 per cent of the patients, whereas no patient showed progression of dysfunction. 11, [25] [26] [27] In the present study a statistically significant improvement occured in neurological signs in the PEM patients after treatment with vitamin E, compared to malnourished controls. The improvement in vibration, joint position sense, dysdiadokinesia, ataxia, tandem walking, and hyporeflexia after treatment was highly significant (p < 0.001). This data corroborate the benefit of vitamin E in other disease states reported earlier. 2, 10, 11 The increase in serum ␣-tocopherol levels and ␣-tocopherol:total lipid ratio after treatment was statistically significant (p < 0.001). Supplementation with ␣-tocopherol acetate (100 mg/kg/day) in the PEM subjects normalized tocopherol levels in 84.8 per cent of cases. This had therapeutic implications.
The CPK levels in 10 PEM subjects showed a statistically significant decline after therapy. The most consistent early feature of vitamin E deficiency is a nutritional muscular dystrophy which is indicated by a rise in CPK levels. The rise in CPK levels has been shown to be reversible post-therapy. 28 Plasma tocopherol concentration correlates closely with total blood lipids in children and adults. 14 The total cholesterol, LDL, triglycerides, and total lipids levels increased after therapy.
Somatosensory evoked potentials may show delayed central conduction consistent with an abnormality of the posterior columns in vitamin E deficiency. 19 Visual evoked responses 29 and brainstem auditory evoked potentials 30 may show prolonged P100 and peak wave latencies, respectively. Stabilization in electrophysiological findings after vitamin E supplementation has been reported. 29 The electrophysiological data in the current study was comparable to normative data, hence no significant change was observed after treatment.
In conclusion the study demonstrated an improvement in neurological signs, normalization of ␣-tocopherol levels, ␣-tocopherol:lipid ratio and 
